a Columbia University.
Am J Bioeth. 2017 Jun;17(6):4-18. doi: 10.1080/15265161.2017.1313334.
The Physician Payments Sunshine Act (PPSA) requires health care product manufacturers to report to the federal government payments more than $10 to physicians. Bringing unprecedented transparency to medicine, PPSA holds great potential for enabling medical stakeholders to manage conflicts of interest (COI) and build patient trust-crucial responsibilities of medical professionalism. The authors conducted six focus groups with 42 physicians in Chicago, IL, San Francisco, CA, and Washington, DC, to explore attitudes and experiences around PPSA. Participants valued the concept of transparency but were wary of the law's design and consequences. They downplayed PPSA's potential and felt it undermined public trust. Showing broad unawareness of COI, they dismissed the notion of industry influence and welcomed company "perks." Misapprehensions may leave physicians unprepared to advance the opportunities PPSA holds for professionalism. The authors offer recommendations for government and medicine to improve physicians' and other stakeholders' understandings and use of the data.
《医师阳光法案》（PPSA）要求医疗产品制造商向联邦政府报告向医生支付的超过 10 美元的款项。该法案为医学带来了前所未有的透明度，对于使医疗利益相关者能够管理利益冲突（COI）和建立患者信任——这是医学专业精神的关键职责——具有巨大的潜力。作者在伊利诺伊州芝加哥、加利福尼亚州旧金山和华盛顿特区进行了六次焦点小组讨论，共有 42 名医生参与，探讨了他们对 PPSA 的态度和经验。参与者重视透明度的概念，但对该法律的设计和后果持谨慎态度。他们低估了 PPSA 的潜力，认为它破坏了公众信任。他们广泛地误解了利益冲突，对行业影响的概念不屑一顾，欢迎公司的“福利”。这些误解可能使医生无法充分利用 PPSA 为专业精神提供的机会。作者为政府和医学界提供了建议，以提高医生和其他利益相关者对数据的理解和使用。
